TRAW TRAWS PHARMA INC

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.

Conference Call and Webcast Information

  • Date: Thursday, August 14, 2025, at 8:30 AM ET
  • Participant Dial-in (U.S.): 1-877-407-0789
  • Participant Dial-in (International): 1-201-689-8562
  • Conference ID: 13754425
  • Webcast Access: 

A replay of the webcast will be available on the Investors section of the Traws website at .

About Traws Pharma, Inc.

Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).

Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws’ website at /partnering.

For more information, please visit and follow us on LinkedIn.

Traws Pharma Contact:

Charles Parker

Traws Pharma, Inc.



Investor Contact:

John Fraunces

LifeSci Advisors, LLC

917-355-2395



EN
08/08/2025

Underlying

TRAWTRAWS PHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TRAWS PHARMA INC

 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursd...

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast...

12h / 58m 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Subm...

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE NEWSWIRE...

June 30, 2025 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB...

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought,...

June 3, 2025 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil a...

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Age...

May 27, 2025 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Reports First Quarter 2025 Results and Business Highlight...

Traws Pharma Reports First Quarter 2025 Results and Business Highlights FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including Long COVID - to be submitted to regulatory authorities in Q2 2025 Cash runway to support planned operations into Q1 2026 NEWTOWN, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch